Lopez Zuñiga, Miguel AngelChueca, Nataliade Salazar, AdolfoFernandez Caballero, Jose AngelGutierrez Valencia, AliciaVinuesa Garcia, DavidOmar Mohamed Balgahata, MohamedHidalgo Tenorio, CarmenLopez-Ruz, Miguel AngelGarcia, Federico2023-02-082023-02-082020-03-17López Zúñiga MÁ, Chueca N, de Salazar A, Fernández Caballero JA, Gutierrez Valencia A, Vinuesa García D, et al. Genetic diversity of HIV in seminal plasma remains higher than in blood after short-term antiretroviral therapy. Sex Transm Infect. 2020 Aug;96(5):337-341http://hdl.handle.net/10668/15323To provide insight on viral kinetics and genetic diversity of HIV in seminal plasma at baseline and 1 month after initiating antiretroviral therapy (ART). Blood and seminal samples from patients with newly diagnosed HIV were obtained before ART initiation (T0) and 1 month after ART initiation (T1). HIV env genetic diversity was studied using deep sequencing Nextera and V3 chemistry in a MiSeq Illumina platform. The number of viral quasispecies (5% cut-off) and Shannon Index were used to analyse diversity. Forty-seven ART-naive patients were recruited between September 2016 and November 2018. At enrolment, the number of quasispecies in blood (median 4 (IQR 2-5)) was lower than in the seminal compartment (median 6, (IQR 4-8)) (p We provide here further evidence of a larger genetic diversity in seminal plasma, both at diagnosis and short term after ART initiation. Our results strengthen previous findings on HIV diversity in seminal plasma. In addition, INIs decrease variability more rapidly than PI and NNRTI in both blood and seminal plasma.enAttribution-NonCommercial 4.0 Internationalhttp://creativecommons.org/licenses/by-nc/4.0/DNA amplificationHIVHIV therapeuticsantiretroviral therapyvirologyAdultAnti-Retroviral AgentsBloodGenetic VariationHIVHIV InfectionsHIV Integrase InhibitorsHIV Protease InhibitorsHumansMaleReverse Transcriptase InhibitorsSemenenv Gene Products, Human Immunodeficiency VirusGenetic diversity of HIV in seminal plasma remains higher than in blood after short-term antiretroviral therapy.research article32245779open accessAntirretroviralesInfecciones por VIHInhibidores de integrasa VIHInhibidores de la proteasa del VIHInhibidores de la transcriptasa inversaVariación genética10.1136/sextrans-2020-0544391472-3263PMC7402555https://sti.bmj.com/content/sextrans/96/5/337.full.pdfhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7402555/pdf